Affimed N.V. (NASDAQ:AFMD) management will conduct a conference call for 10th November 2020 at 8:30 AM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.affimed.com
Earnings Expectation
Affimed N.V. is set to announce third quarter earning results on Tuesday 10th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, AFMD to report 3Q20 loss of $ 0.1 per share. For the full year, analysts anticipate top line of $ 26.62 million, while looking forward to loss of $ 0.52 per share bottom line.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The companys products include AFM24, an innate cell-engaging bispecific antibody that treats patients suffering of EGFR expressing solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.
